Evolution, determinants and regulation of drug expenditures in France
© 2018 médecine/sciences – Inserm..
According to the Organization for Economic Co-operation and Development (OECD), drug expenditures account for about 20 % of all health expenditures in high-income countries. The increase of these drug expenditures which has been observed in all these countries over a long period is due to the combination of aging populations, changes in medical practices and the dynamics of the pharmaceutical market, in particular the hospital market. France is no exception. Its consumption of drugs (which accounted for 17.5 % of health expenditures in 2014), historically among the highest in volume, has grown slower in the last decade than in other OECD countries. However, the particularly rapid and wide adoption of pharmaceutical innovations, which has always characterized France, has had in recent years a very significant effect on the soaring drug expenditures covered by the social protection system (plus 1.1 billion in 2014, a year marked by the introduction of new therapies against hepatitis C). This significant effect should continue with the introduction of new and very expensive therapies, particularly in oncology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Medecine sciences : M/S - 34(2018), 1 vom: 25. Jan., Seite 83-86 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Évolution, déterminants et régulation des dépenses de médicaments en France |
|---|
| Beteiligte Personen: |
Le Galès, Catherine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 31.08.2018 Date Revised 31.08.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1051/medsci/20183401018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM280442300 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM280442300 | ||
| 003 | DE-627 | ||
| 005 | 20231225025335.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1051/medsci/20183401018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0934.xml |
| 035 | |a (DE-627)NLM280442300 | ||
| 035 | |a (NLM)29384101 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Le Galès, Catherine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evolution, determinants and regulation of drug expenditures in France |
| 246 | 3 | 3 | |a Évolution, déterminants et régulation des dépenses de médicaments en France |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.08.2018 | ||
| 500 | |a Date Revised 31.08.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2018 médecine/sciences – Inserm. | ||
| 520 | |a According to the Organization for Economic Co-operation and Development (OECD), drug expenditures account for about 20 % of all health expenditures in high-income countries. The increase of these drug expenditures which has been observed in all these countries over a long period is due to the combination of aging populations, changes in medical practices and the dynamics of the pharmaceutical market, in particular the hospital market. France is no exception. Its consumption of drugs (which accounted for 17.5 % of health expenditures in 2014), historically among the highest in volume, has grown slower in the last decade than in other OECD countries. However, the particularly rapid and wide adoption of pharmaceutical innovations, which has always characterized France, has had in recent years a very significant effect on the soaring drug expenditures covered by the social protection system (plus 1.1 billion in 2014, a year marked by the introduction of new therapies against hepatitis C). This significant effect should continue with the introduction of new and very expensive therapies, particularly in oncology | ||
| 650 | 4 | |a Journal Article | |
| 773 | 0 | 8 | |i Enthalten in |t Medecine sciences : M/S |d 1996 |g 34(2018), 1 vom: 25. Jan., Seite 83-86 |w (DE-627)NLM08683102X |x 1958-5381 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2018 |g number:1 |g day:25 |g month:01 |g pages:83-86 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1051/medsci/20183401018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2018 |e 1 |b 25 |c 01 |h 83-86 | ||